The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members - Westerhof, Ilse; Sikkema, Reina; Rozhnova, Ganna; van Beek, Janko; Koopmans, Marion; Bruijning-Verhagen, Patricia (medRxiv, 2024)
Background/Rationale We investigated the effect of pre-existing antibodies against SARS-CoV-2 and seasonal human coronaviruses on infection outcomes in Omicron BA1/2 exposed household members from January to March 2022.Methods Data from a prospective household study in the Netherlands were used including 63 households with 195 household members exposed to a SARS-CoV-2 Omicron BA1/2 index case. The protocol included repeated nose-throat swab and saliva RT-PCR testing, paired serology, and self-reported daily symptom scoring by household members. Infection outcomes included the occurrence of secondary infections, symptom severity, and CT-value trajectories. We studied the effect of baseline binding antibody levels for SARS-CoVs and seasonal coronaviruses (hCoV) NL63, 229E, HKU1 and OC43 spike protein, on SARS-CoV-2 infection outcomes.Results 132 of 195 (68%) exposed household members developed a SARS-CoV-2 infection. Among exposed household members, higher levels of SARS-CoV-2 and beta hCoV antibodies (HKU1 and OC43) at baseline, were associated with a reduced risk of secondary infection (adjusted Odds ratio 0.61; 95% Confidence interval 0.44-0.84 and aOR 0.72; 95%CI 0.56-0.92, respectively). No significant differences between antibody levels and symptom burden or CT-value trajectories were observed.Conclusions Our study suggests that prior SARS-CoV-2 and beta hCoV antibodies provide some protection against Omicron BA.1/BA.2 infection, while effects on symptom burden or CT-value could not be demonstrated. The results highlight the relatively limited, but not negligible role of cross-protective antibodies, especially when facing immune escape variants of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work forms part of RECOVER (Rapid European COVID-19 Emergency Response research) and VERDI (SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts). RECOVER (101003589) is funded by the European Union (EU) Horizon 2020 research and innovation program. VERDI project (101045989) is funded by the EU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the EU or the European Health and Digital Executive Agency. Neither the EU nor the granting authority can be held responsible for them. GR was supported by Fundacao para a Ciencia e a Tecnologia project 2022.01448.PTDC, DOI 10.54499/2022.01448.PTDC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and ethically approved by the Medical Ethical committee Utrecht, The Netherlands (reference number 17-069/M).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data analyzed for this manuscript are not publicly available due to privacy concerns. The data contain sensitive personal information, and sharing these data could compromise participant confidentiality. For more information, please contact the corresponding author.